Middle East and Africa Central Precocious Puberty (CPP) Treatment Market – Industry Trends and Forecast to 2027

  • Pharmaceutical
  • Published Report
  • Sep 2020
  • MEA
  • 350 Pages
  • No of Tables: 161
  • No of Figures: 45

Middle East and Africa Central Precocious Puberty (CPP) Treatment market, By Type (Medication, Surgery), Month (1-Month, 3-Month, 6-Month, Others), Route of Administration (Parenteral, Oral, Implants, Others), Gender (Girls, Boys), End User (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others), Country (South Africa, Saudi Arabia, U.A.E., Israel, Egypt, Kuwait and Rest of Middle East and Africa) Industry Trends and Forecast to 2027      

Middle East and Africa Central Precocious Puberty (CPP) Treatment MarketMarket Analysis and Insights: Middle East and Africa Central Precocious Puberty (CPP) Treatment Market

Middle East and Africa central precocious puberty (CPP) treatment market is expected to gain market growth in the forecast period of 2020 to 2027.  Data Bridge Market Research analyses that the market is growing with a CAGR of 5.9% in the forecast period of 2020 to 2027 and is expected to reach Euro 18.48 million by 2027. Favorable government support for product approval and increasing prevalence of obesity are the major drivers which propelled the demand of the market in the forecast period.  

Central precocious puberty (CPP) treatment comprises features such as presence of novel pipeline drugs which will impact in launching new products by the manufacturers into the central precocious puberty (CPP) treatment market which enhance its demand as well as high demand of disease specific treatment leads the demand of accurate central precocious puberty (CPP) treatment.

Currently, various research studies are taking place which is expected to create a competitive advantage for manufacturers to develop new and innovative central precocious puberty (CPP) treatment which is expected to provide various other opportunities in the central precocious puberty (CPP) treatment market. However, inadequate reimbursement policies and patent expiry are expected to restraint the central precocious puberty (CPP) treatment market growth in the forecast period.     

The central precocious puberty (CPP) treatment market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the central precocious puberty (CPP) treatment market scenario contact Data Bridge Market Research for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.  

Middle East and Africa Central Precocious Puberty (CPP) Treatment MarketMiddle East and Africa Central precocious puberty (CPP) Treatment Market Scope and Market Size

Central precocious puberty (CPP) treatment market is segmented on the basis of type, months, route of administration, gender, end user and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.  

  • On the basis of type, the central precocious puberty (CPP) treatment market is segmented into medication and surgery. In 2020, medication segment is dominating in the central precocious puberty (CPP) treatment market because of children with CPP, with no underlying serious conditions can be effectively treated with medication and medication is the first choice for the management and treatment of CPP.
  • On the basis of month, the central precocious puberty (CPP) treatment market is segmented into 1-month, 3-month, 6-month, and others. In 2020, 1-month segment is dominating in the central precocious puberty (CPP) treatment market because the children suffering from initial stages of CPP are administered with ne month drug dosage so as to check the efficacy of treatment.
  • On the basis of route of administration, the central precocious puberty (CPP) treatment market is segmented into parenteral, oral, implants, others. In 2020, parenteral segment is dominating in the central precocious puberty (CPP) treatment market because as medicines administered through parenteral route are not subjected to gastrointestinal tract and hence provide efficacious result at low drug dosage.
  • On the basis of gender, the central precocious puberty (CPP) treatment market is segmented into girls and boys. In 2020, girls segment is dominating in the central precocious puberty (CPP) treatment market as due to increasing girls to boys ratio, moreover this has been reported that girls are 10 time more prone to precocious puberty as compared to that of the boys. 
  • On the basis of end user, the central precocious puberty (CPP) treatment market is segmented into hospitals, specialty clinics, homecare, and others. In 2020, hospitals segment is dominating in the central precocious puberty (CPP) treatment market due to improving healthcare infrastructure and presence of trained drug administrators.
  • On the basis of distribution channel, the central precocious puberty (CPP) treatment market is segmented into direct tender, hospital pharmacies, retail pharmacies, online pharmacies, and others. In 2020, direct tender segment is dominating in the market because most of the healthcare facilities are dependent on direct tenders for purchase of drugs in bulk amount at a reduced cost. 

Middle East & Africa Central Precocious Puberty (CPP) Treatment Market Country Level Analysis

The central precocious puberty (CPP) treatment market is analyzed and market size information is provided by country, type, months, route of administration, gender, end user and distribution channel as referenced above.

The countries covered in the Middle East & Africa central precocious puberty (CPP) treatment market report are the South Africa, Saudi Arabia, U.A.E., Israel, Egypt, Kuwait and rest of Middle East and Africa.       

The Middle East & Africa region is expected to grow with the highest growth rate in the forecast period of 2020 to 2027 because of rising awareness programmers by the pharmaceutical industries and government for the betterment of children health. Saudi Arabia is leading the growth of the Middle East & Africa central precocious puberty (CPP) treatment market due to rise rising pharmaceutical industries in the region.    

The country section of the Middle East & Africa central precocious puberty (CPP) treatment market report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of Middle East & Africa brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.   

Presence of Strong Product Pipeline and Growing Prevalence of Hormonal Disorders are boosting the Central Precocious Puberty (CPP) Treatment Market Growth

Middle East and Africa central precocious puberty (CPP) treatment market also provides you with detailed market analysis for every country growth in central precocious puberty (CPP) treatment industry with central precocious puberty (CPP) treatment drugs sales, impact of advancement in the central precocious puberty (CPP) treatment technology and changes in regulatory scenarios with their support for the central precocious puberty (CPP) treatment market. The data is available for historic period 2010 to 2018.   

Competitive Landscape and Central precocious puberty (CPP) Treatment Market Share Analysis

Central precocious puberty (CPP) treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breath, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to central precocious puberty (CPP) treatment market.

The major companies which are dealing in the Middle East and Africa central precocious puberty (CPP) treatment market are Ipsen Pharma, AbbVie Inc., Mylan N.V., Pfizer Inc., Takeda Pharmaceutical Company Limited, Sanofi, AstraZeneca, Sun Pharmaceutical Industries Ltd among others.

Many product launch and agreement are also initiated by the companies’ worldwide which are also accelerating the central precocious puberty (CPP) treatment market.

For instance,

  • In July  2019, Pfizer Inc. went under collaboration with Mylan N.V. with an aim to improve the generics drug portfolio. The company is engaged in manufacturing of generic medicines for CPP treatment, thus this collaboration strengthened the company’s foot in central precocious puberty (CPP) treatment market.
  • In January 2019, Takeda Pharmaceutical Company Limited acquired the Shire plc a company engaged in manufacturing of medicines for treatment of central precocious puberty. This acquisition strengthened the company’s product portfolio for central precocious puberty (CPP) treatment.

Collaboration, product launch, business expansion, award and recognition, joint ventures and other strategies by the market players is enhancing the company market in the central precocious puberty (CPP) treatment market which also provides the benefit for organization to improve their offering for central precocious puberty (CPP) treatment.

Customization Available : Middle East and Africa Central Precocious Puberty (CPP) Treatment Market

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.


SKU-

LIST OF TABLES 

TABLE 1 MIDDLE EAST & AFRICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, PIPELINE ANALYSIS

TABLE 2 GENERIC DRUGS FOR CENTRAL PRECOCIOUS PUBERTY

TABLE 3 MEDICINES SUBJECTED TO PATENT EXPIRY

TABLE 4 MIDDLE EAST & AFRICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE, 2019-2027 (EURO MILLION)

TABLE 5 MIDDLE EAST & AFRICA MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP)TREATMENT MARKET, BY REGION, 2017-2027 (EURO MILLION)

TABLE 6 MIDDLE EAST & AFRICA MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 7 MIDDLE EAST & AFRICA LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 8 MIDDLE EAST & AFRICA LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 9 MIDDLE EAST & AFRICA LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 10 MIDDLE EAST & AFRICA TRIPTORELIN  IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 11 MIDDLE EAST & AFRICA TRIPTORELIN  IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 12 MIDDLE EAST & AFRICA HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 13 MIDDLE EAST & AFRICA HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 14 MIDDLE EAST & AFRICA ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 15 MIDDLE EAST & AFRICA SURGERIES IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY REGION, 2017-2027 (EURO MILLION)

TABLE 16 MIDDLE EAST & AFRICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH, 2019-2027 (EURO MILLION)

TABLE 17 MIDDLE EAST & AFRICA 1- MONTH IN CENTRAL PRECOCIOUS PUBERTY (CPP)TREATMENT MARKET, BY REGION, 2017-2027 (EURO MILLION)

TABLE 18 MIDDLE EAST & AFRICA 3- MONTH IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY REGION, 2017-2027 (EURO MILLION)

TABLE 19 MIDDLE EAST & AFRICA 6- MONTH IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY REGION, 2017-2027 (EURO MILLION)

TABLE 20 MIDDLE EAST & AFRICA OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY REGION, 2017-2027 (EURO MILLION)

TABLE 21 MIDDLE EAST & AFRICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2027 (EURO MILLION)

TABLE 22 MIDDLE EAST & AFRICA PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY REGION, 2017-2027 (EURO MILLION)

TABLE 23 MIDDLE EAST & AFRICA PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 24 MIDDLE EAST & AFRICA ORAL IN CENTRAL PRECOCIOUS PUBERTY (CPP)TREATMENT MARKET, BY REGION, 2017-2027 (EURO MILLION)

TABLE 25 MIDDLE EAST & AFRICA IMPLANT IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY REGION, 2017-2027 (EURO MILLION)

TABLE 26 MIDDLE EAST & AFRICA OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY REGION, 2017-2027 (EURO MILLION)

TABLE 27 MIDDLE EAST & AFRICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER, 2019-2027 (EURO MILLION)

TABLE 28 MIDDLE EAST & AFRICA GIRLS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY REGION, 2017-2027 (EURO MILLION)

TABLE 29 MIDDLE EAST & AFRICA BOYS IN CENTRAL PRECOCIOUS PUBERTY (CPP)TREATMENT MARKET, BY REGION, 2017-2027 (EURO MILLION)

TABLE 30 MIDDLE EAST & AFRICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER, 2019-2027 (EURO MILLION)

TABLE 31 MIDDLE EAST & AFRICA HOSPITALS IN CENTRAL PRECOCIOUS PUBERTY (CPP)TREATMENT MARKET, BY REGION, 2017-2027 (EURO MILLION)

TABLE 32 MIDDLE EAST & AFRICA SPECILATY CLINICS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY REGION, 2017-2027 (EURO MILLION)

TABLE 33 MIDDLE EAST & AFRICA HOME CARE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY REGION, 2017-2027 (EURO MILLION)

TABLE 34 MIDDLE EAST & AFRICA OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY REGION, 2017-2027 (EURO MILLION)

TABLE 35 MIDDLE EAST & AFRICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 (EURO MILLION)

TABLE 36 MIDDLE EAST & AFRICA DIRECT TENDER IN CENTRAL PRECOCIOUS PUBERTY (CPP)TREATMENT MARKET, BY REGION, 2017-2027 (EURO MILLION)

TABLE 37 MIDDLE EAST & AFRICA HOSPITAL PHARMACIES IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY REGION, 2017-2027 (EURO MILLION)

TABLE 38 MIDDLE EAST & AFRICA RETAIL PHARMACIES IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY REGION, 2017-2027 (EURO MILLION)

TABLE 39 MIDDLE EAST & AFRICA ONLINE PHARMACIES IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY REGION, 2017-2027 (EURO MILLION)

TABLE 40 MIDDLE EAST & AFRICA OTHERS IN CNETRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY REGION, 2018-2027 (EURO MILLION)

TABLE 41 MIDDLE EAST & AFRICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY COUNTRY, 2018-2027 (EURO MILLION)

TABLE 42 MIDDLE EAST & AFRICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 43 MIDDLE EAST & AFRICA MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 44 MIDDLE EAST & AFRICA LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 45 MIDDLE EAST & AFRICA ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 46 MIDDLE EAST & AFRICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 47 MIDDLE EAST & AFRICA LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 48 MIDDLE EAST & AFRICA LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 49 MIDDLE EAST & AFRICA HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 50 MIDDLE EAST & AFRICA HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 51 MIDDLE EAST & AFRICA TRIPTORELIN  IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 52 MIDDLE EAST & AFRICA TRIPTORELIN  IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 53 MIDDLE EAST & AFRICA OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 54 MIDDLE EAST & AFRICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 55 MIDDLE EAST & AFRICA PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 56 MIDDLE EAST & AFRICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)

TABLE 57 MIDDLE EAST & AFRICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)

TABLE 58 MIDDLE EAST & AFRICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)

TABLE 59 SAUDI ARABIACENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 60 SAUDI ARABIA MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 61 SAUDI ARABIA LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 62 SAUDI ARABIAADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 63 SAUDI ARABIACENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 64 SAUDI ARABIALEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 65 SAUDI ARABIALEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 66 SAUDI ARABIAHISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 67 SAUDI ARABIAHISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 68 SAUDI ARABIATRIPTORELIN  IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 69 SAUDI ARABIATRIPTORELIN  IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 70 SAUDI ARABIAOTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 71 SAUDI ARABIACENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 72 SAUDI ARABIAPARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 73 SAUDI ARABIA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)

TABLE 74 SAUDI ARABIACENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)

TABLE 75 SAUDI ARABIACENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)

TABLE 76 SOUTH AFRICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 77 SOUTH AFRICA MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 78 SOUTH AFRICA LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 79 SOUTH AFRICA ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 80 SOUTH AFRICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 81 SOUTH AFRICA LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 82 SOUTH AFRICA LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 83 SOUTH AFRICA HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 84 SOUTH AFRICA HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 85 SOUTH AFRICA TRIPTORELIN  IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 86 SOUTH AFRICA TRIPTORELIN  IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 87 SOUTH AFRICA OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 88 SOUTH AFRICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 89 SOUTH AFRICA PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 90 SOUTH AFRICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)

TABLE 91 SOUTH AFRICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)

TABLE 92 SOUTH AFRICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)

TABLE 93 UAE. CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 94 UAE. MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 95 UAE. LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 96 UAE. ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 97 UAE. CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 98 UAE. LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 99 UAE. LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 100 UAE. HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 101 UAE. HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 102 UAE. TRIPTORELIN  IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 103 UAE. TRIPTORELIN  IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 104 UAE. OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 105 UAE. CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 106 UAE. PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 107 UAE. CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)

TABLE 108 UAE. CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)

TABLE 109 UAE. CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)

TABLE 110 ISRAEL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 111 ISRAEL MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 112 ISRAEL LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 113 ISRAEL ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 114 ISRAEL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 115 ISRAEL LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 116 ISRAEL LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 117 ISRAEL HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 118 ISRAEL HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 119 ISRAELTRIPTORELIN  IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 120 ISRAELTRIPTORELIN  IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 121 ISRAEL OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 122 ISRAEL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 123 ISRAEL PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 124 ISRAEL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)

TABLE 125 ISRAEL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)

TABLE 126 ISRAEL CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)

TABLE 127 EGYPT CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 128 EGYPT MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 129 EGYPT LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 130 EGYPT ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 131 EGYPT CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 132 EGYPT LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 133 EGYPT LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 134 EGYPT HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 135 EGYPT HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 136 EGYPT TRIPTORELIN  IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 137 EGYPT TRIPTORELIN  IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 138 EGYPT OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 139 EGYPT CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 140 EGYPT PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 141 EGYPT CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)

TABLE 142 EGYPTCENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)

TABLE 143 EGYPT CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)

TABLE 144 KUWAIT CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 145 KUWAIT MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 146 KUWAIT LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 147 KUWAIT ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 148 KUWAIT CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 149 KUWAIT LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 150 KUWAIT LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 151 KUWAIT HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 152 KUWAIT HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 153 KUWAIT TRIPTORELIN  IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 154 KUWAIT TRIPTORELIN  IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 155 KUWAIT OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 156 KUWAIT CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 157 KUWAIT PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 158 KUWAIT CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)

TABLE 159 KUWAIT CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)

TABLE 160 KUWAIT CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)

TABLE 161 REST OF MIDDLE EAST & AFRICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

CHOOSE LICENCE TYPE
  • 4200.00
  • 3500.00
  • 2000.00
  • 5500.00
  • 7500.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19